Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | MonumenTAL-1: talquetamab for multiple myeloma

Amrita Krishnan, MD, City of Hope, Duarte, CA, shares her highlights on the latest myeloma advancements presented at ASH 2021. Dr Krishnan summarizes important information regarding the MonumenTAL-1 study (NCT04634552), which is investigating the recent use of talquetamab, a GPRC5D, CD3 bispecific antibody, for the treatment of myeloma. First, Dr Krishnan describes the dosing schedules used, and further explains some of the side effects experienced by patients, including onychomadesis and mild cytokine release. Following this, Dr Krishnan draws focus to the exciting prospects and potential future uses of talquetamab in myeloma therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.